{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-001773","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.267964+00:00","generated_at":"2026-06-27T00:04:55.981950+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q4 2021 net loss $37.7M; cash $205.8M; pipeline advances with 3 candidates in clinic","bullets":["Net loss Q4 2021 $37.7M ($0.89/share) vs $34.4M in Q4 2020; full year loss $128.3M ($3.22/share).","Cash and investments $205.8M at Dec 31, 2021; sufficient to fund operations into first half 2024.","CAM (ALG-000184) shows best-in-class HBV DNA/RNA reductions; 12-week studies planned for H2 2022.","ASO (ALG-020572) Phase 1b in CHB initiated, first cohort enrolled; data expected at a conference in H2 2022.","Expanded Merck NASH collaboration for second oligonucleotide target; COVID-19 3CL PI candidates more potent than nirmatrelvir."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-001773","json":"https://secwatch.observer/filing/0001171843-22-001773.json","markdown":"https://secwatch.observer/filing/0001171843-22-001773.md","text":"https://secwatch.observer/filing/0001171843-22-001773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322001773/0001171843-22-001773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322001773/f8k_031022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:04:55.981950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}